New combo therapy shows early promise for hard-to-treat colorectal cancer
NCT ID NCT02512172
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested whether adding two drugs (romidepsin and 5-azacitidine) to an immunotherapy (MK-3475) could help shrink tumors in people with a type of advanced colorectal cancer that usually doesn't respond to immunotherapy. 27 adults with microsatellite stable (MSS) colorectal cancer who had already tried standard treatments took part. The main goals were to check safety and see if the combination increased immune cells in the tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21205, United States